Alembic Pharma shines on getting USFDA’s final nod for Valganciclovir for Oral Solution
Mumbai, October 28 (Udaipur Kiran): Alembic Pharmaceuticals is currently trading at Rs. 785.00, up by 14.05 points or 1.82% from its previous closing of Rs. 770.95 on the BSE.
The scrip opened at Rs. 770.05 and has touched a high and low of Rs. 785.90 and Rs. 769.50 respectively. So far 2523 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 998.00 on 04-Nov-2025 and a 52 week low of Rs. 635.30 on 23-Mar-2026.
Last one week high and low of the scrip stood at Rs. 795.00 and Rs. 748.80 respectively. The current market cap of the company is Rs. 15447.90 crore.
The promoters holding in the company stood at 69.87%, while Institutions and Non-Institutions held 19.98% and 10.15% respectively.
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Valganciclovir for Oral Solution, 50 mg/mL. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Valcyte for Oral Solution 50 mg/mL of CHEPLAPHARM Arzneimittel GmbH (CHEPLAPHARM).
Valganciclovir for oral solution is indicated for treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS); and for prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk.
Alembic has a cumulative total of 247 ANDA approvals (227 final approvals and 20 tentative approvals) from the USFDA.
Alembic Pharmaceuticals is involved in manufacturing and marketing of India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.